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Abstract: Carbapenem-resistant (CR) Gram-negative infections, including those caused by
Enterobacteriaceae and the non-fermenters, represent the greatest unmet need for new effective
treatments. The clinical development of new antibiotics for the treatment of CR infections is
challenging and should focus on the individual pathogens irrespective of the infection site.
However, the drug approval pathway is generally infection-site specific and rarely includes such
drug-resistant pathogens. To overcome this limitation, a streamlined clinical development program
may include a pathogen-focused clinical study, such as the CREDIBLE-CR study, to meet the
expectations of some health authorities (ie, the EuropeanMedicinesAgency [EMA]) and themedical
community. Cefiderocol is a novel siderophore cephalosporin designed to target CR pathogens,
including CR strains of Enterobacteriaceae (CRE), Pseudomonas aeruginosa, Acinetobacter bau-
mannii, and also Stenotrophomonas maltophilia, which is intrinsically CR. The CREDIBLE-CR
studywas planned to evaluate cefiderocol in patients with CRGram-negative infections regardless of
species or infection-site source. Rapid diagnostic testing and/or selective media were provided to
facilitate detection of CR pathogens to rapidly enroll patients with nosocomial pneumonia, blood-
stream infection/sepsis, or complicated urinary tract infection. Patients were randomized 2:1 to
receive cefiderocol or best available therapy. There were no pre-specified statistical hypotheses for
this study, as the sample size was driven by enrollment feasibility and not based on statistical power
calculations. The objective of the CREDIBLE-CR study was to provide descriptive evidence of the
efficacyand safety of cefiderocol for the target populationof patientswithCR infections, including the
non-fermenters. The CREDIBLE-CR study is currently the largest pathogen-focused, randomized,
open-label, prospective, Phase 3 clinical study to investigate a new antibiotic in patients with CR
Gram-negative infections.Herewedescribe the design of this pathogen-focused study and steps taken
to aid patient enrollment into the study within an evolving regulatory environment.
ClinicalTrials.gov registration: NCT02714595.
EUDRA-CT registration: 2015-004703-23.
Keywords: best available therapy, cefiderocol, carbapenem resistance, pathogen-focused
study design, rapid diagnostics, streamlined/limited clinical development
Introduction
The increased burden of drug-resistant bacteria on healthcare systems1 and patients
in terms of quality of life2 is well recognized globally, with carbapenem-resistant
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(CR) strains of Acinetobacter baumannii, Pseudomonas
aeruginosa, Escherichia coli, and Klebsiella pneumoniae
being listed by the World Health Organization as the high-
est priority for new antibiotics development.3 Furthermore,
Stenotrophomonas maltophilia, which is intrinsically resis-
tant to carbapenems, and CR strains of Burkholderia spp.
are difficult-to-treat non-fermenter pathogens in certain
patient populations.4,5 These CR pathogens can cause ser-
ious infections such as nosocomial pneumonia, bactere-
mia, sepsis, urinary tract infections, intra-abdominal
infections, and even skin and soft tissue infections,6,7 and
represent a high unmet medical need.2
Patients infected by CR pathogens often present with sig-
nificant comorbidities and a history of prior hospitalization,
require admission to the intensive care unit (ICU),7–9 and are
at an increased risk of mortality merely due to the severity of
their illness.7,10–12 One pooled analysis of several studies has
shown an attributable mortality rate of approximately 26%–
44% due to carbapenem-resistant Enterobacteriaceae (CRE) in
patients diagnosed with sepsis, bacteremia, and/or nosocomial
pneumonia,13 while the in-hospital all-cause mortality rate
approached 48%–69%.
Cefiderocol is a novel siderophore cephalosporin devel-
oped by Shionogi with the purpose of broadly treating CR
Gram-negative infections, including those caused by both the
family Enterobacteriaceae and non-fermenters such as A. bau-
mannii, P. aeruginosa, and S.maltophilia,14,15 regardless of the
underlying carbapenem resistance mechanism. As a sidero-
phore, cefiderocol sequesters iron from the host and efficiently
crosses the outer membrane utilizing the bacteria’s active iron
transport channels, and its specific side chains provide struc-
tural stability against all Ambler classes of β-lactamases,
including metallo-β-lactamases (MBLs).14,16–18 The active
transport via the outer membrane means that cefiderocol over-
comes resistance related to loss of porin channel function or
upregulation of efflux pumps.15 Cefiderocol has demonstrated
potent in vitro activity against Gram-negative bacteria,15,19,20
which has been confirmed in the ongoing global SIDERO-WT
surveillance studies (ie, 99% of the isolates with a minimum
inhibitory concentration of ≤4 μg/mL), including carbapenem-
or meropenem-non-susceptible strains.21–24 The broad spec-
trum of Gram-negative activity provides an opportunity to
develop cefiderocol as a Gram-negative antibiotic, not
restricted by species or mechanism of carbapenem resistance.
Cefiderocol has been investigated in extensive pre-
clinical and Phase 1 development programs to describe
its pharmacokinetic and pharmacodynamic (PK/PD) pro-
file and to establish the dosing regimens for the treatment
of patients with infections, including those with underlying
renal disease.25–31 A first-in-human infection Phase 2
study in patients with complicated urinary tract infection
(cUTI) in a patient population at risk for multidrug-resis-
tant infections has been completed and demonstrated non-
inferiority to imipenem-cilastatin in the primary endpoint
and additionally superiority in the composite and micro-
biological responses in a post hoc analysis.32 To date,
cefiderocol is the only siderophore cephalosporin that has
reached late-stage clinical development, with two rando-
mized Phase 3 studies, one of which is the pathogen-
focused CREDIBLE-CR study described in this article.
Including target CR pathogens when developing new anti-
biotic agents may be challenging primarily due to the fact that
they are still relatively uncommon pathogens in relation to the
overall disease burden in all diagnoses.2,6,33,34 The recently
approved β-lactam–β-lactamase inhibitor (BL-BLI) combina-
tion drugs (eg, ceftazidime-avibactam, meropenem-vaborbac-
tam, or ceftolozane-tazobactam) demonstrate in vitro activity
against many CREs or CR P. aeruginosa, respectively, but
have limited potency against those strains expressing MBLs
or the non-fermenters.12,35,36 These drugs have been investi-
gated in traditional infection site-specific randomized, double-
blind, non-inferiority, Phase 3 clinical studies, in which the
proportions of CR strains were negligible.37–42 Previous open-
label superiority studies addressing mainly CR A. baumannii
infections investigated colistin ± rifampicin or ± meropenem
but failed to show superiority of the combination regimens, and
were associated with high treatment failure (73%–79%) and
mortality (43%–45%) rates, demonstrating the lack of consis-
tent benefit of these agents in monotherapy or in
combination.10,43,44
The early detection of CR pathogens is of paramount
importance because delaying appropriate antibiotic therapy
against resistant pathogens (ie, >48 hrs) significantly increases
the risk of treatment failure and mortality.45,46 This clinical
fact results in immediate empiric use of broad-spectrum anti-
biotics, including antibiotics that might be active against CR
pathogens (eg, colistin). This in turn makes it difficult to enroll
patients into prospective randomized clinical trials of new
antibiotics, where a limited time window of 24–36 hrs of
prior active antibiotics excludes patients from the study as
assessment of treatment effect may be confounded.
Enrollment of patients with CR infections without delaying
effective antibiotic therapy might be facilitated by the use of
rapid diagnostic methods, which can detect CREs directly
from different biospecimens.47–49 Indeed, recent evidence
suggests that implementation of rapid diagnostics into clinical
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practice can reduce the time to appropriate antibiotic therapy
with a favorable impact on patient outcomes.47,50–52 This
suggests that rapid diagnostics could be a valuable tool in
clinical investigations of new antibiotics.
The selection of the comparator antibiotic for a double-
blind, randomized, prospective study is also problematic
when the target pathogens include both CRE and CR non-
fermenters. Standard-of-care treatment often involves a
combination of agents even in the absence of in vitro
activity and are also selected based on the specific patho-
gen and the site of infection.53 An antibiotic which might
be considered an appropriate choice for KPC-producing
Klebsiella pneumoniae might be inappropriate for A. bau-
mannii. This is further complicated by the availability of
different antibiotics in different countries (eg, intravenous
fosfomycin), and by availability of new antibiotics during
the enrollment period of the study (eg, ceftazidime-avibac-
tam). The antibiotic options for the treatment of CR infec-
tions are limited to older antibiotics (eg, colistin,
fosfomycin, aminoglycosides, tigecycline) and the recently
approved BL-BLI combination drugs when the pathogens
show susceptibility.54,55 Therefore, selection of a fixed
single or combination antibiotic as the comparator for a
double-blind, randomized, international, multicenter clin-
ical investigation is not feasible when susceptibility rates
to these agents of CR Enterobacteriaceae, P. aeruginosa,
and A. baumannii vary greatly across countries and only
best available (mono or combo) therapy would be pre-
scribed for patients as standard of care.
This article describes the design of the CREDIBLE-CR
study and the key elements that address the challenges to
recruitment of patients into pathogen-focused clinical trials
under an evolving regulatory environment. The objective
of the randomized, international, open-label, parallel-
group, Phase 3 CREDIBLE-CR study was to assess the
efficacy and safety (and PK parameters) of cefiderocol or
best available therapy (BAT) in hospitalized patients with
evidence of CR infections, including patients with hospi-
tal-acquired pneumonia (HAP), ventilator-associated
pneumonia (VAP), healthcare-associated pneumonia
(HCAP), or bloodstream infections (BSI) or sepsis, or
cUTI caused by CR Gram-negative bacteria. The study
has been conducted under a streamlined/limited clinical
development program, which enabled the enrollment of
patients with various diagnoses and a broad range of CR
bacteria according to the guidance outlined by the
European Medicines Agency (EMA).56–59
Methods And Patients
Overall Study Design
The CREDIBLE-CR study is a prospective, international,
multicenter, open-label, parallel-group, randomized, Phase 3
clinical study (NCT02714595;60 2015-004703-2361), which
enrolled patients with HAP/VAP/HCAP, BSI or sepsis (with
a primary source that was not bacteremia), and cUTI caused by
documented CR Gram-negative pathogens, including A. bau-
mannii, P. aeruginosa, S. maltophilia, K. pneumoniae, E. coli,
or other species in the family of Enterobacteriaceae (and in the
updated order of Enterobacterales62,63). Patients meeting elig-
ibility criteria were randomized 2:1 to receive either intrave-
nous (IV) cefiderocol 2 g, q8h, infused over 3 hrs (with one
adjunctive antibiotic with Gram-negative coverage permitted
if considered necessary, except for cUTI), or IV BAT which
included up to three antibiotics used in combination for 7–14
days, although treatment duration could be extended up to 21
days at the discretion of the investigator.
Ethics
The study was conducted according to the requirements out-
lined by institutional review boards or institutional ethics
committees of the participating clinical sites (Supplemental
Table 1), and according to the principles of the International
Conference on Harmonization Good Clinical Practice and
those outlined in the Declaration of Helsinki. Prior to partici-
pation in the study, patients or their legal representatives
provided signed informed consent. Additional informed con-
sent was required from patients or their legal representatives if
rapid diagnostic testing was used to confirm the presence of
CR Gram-negative bacteria. The study protocol, the general
informed consent form, and the rapid diagnostics informed
consent formwere approved by the institutional review boards
or local ethics committees (Supplemental Table 1).
Participants
Adult patients who had an infection caused by a documented
CR Gram-negative pathogen and were expected to require
hospitalization and IV antibiotic therapy for 7–14 days were
eligible for enrollment. Patients had to be at least 18 years old
at the time of providing informed consent.
Inclusion Criteria
Patients who were diagnosed with HAP/VAP/HCAP, BSI or
sepsis, or cUTI were enrolled into the study. Each clinical
diagnosis had specific inclusion criteria, as shown in Table 1.
Additionally, all enrolled patients had an evidence of CR
Dovepress Bassetti et al
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Gram-negative infection at the primary infection site that
could be confirmed by at least one of the following five
methods: (1) documented treatment failure while on empiric
antibiotic therapy with a CR Gram-negative pathogen con-
firmed by the respective culture/susceptibility testing; (2) rapid
diagnostics used on an appropriate clinical biospecimen to
confirm a CR pathogen; (3) the local hospital antibiogram
demonstrated >90% rate of carbapenem resistance among
local pathogens and the sample obtained from the patient
was confirmed to contain at least one of these resistant patho-
gens; (4) the pathogen was confirmed as S. maltophilia, which
has intrinsic resistance to carbapenems; or (5) the patient was
confirmed to be colonized at the site of the primary infection
with CR Gram-negative bacteria within 72 hrs prior to enroll-
ment and randomization.
Exclusion Criteria
Patients were not eligible for enrollment if any of the following
applied: they had received a potentially effective antibiotic
regimen for the current CR infection within 72 hrs prior to
randomization for a continuous duration of ≥24 hrs in cUTI, or
≥36 hrs in HAP/VAP/HCAP or BSI/sepsis; they had moderate
or severe hypersensitivity or allergic reaction to any β-lactam
antibiotic; they required >3 systemic antibiotics for the treat-
ment of the current infection if randomized to the BAT arm;
they had concurrent invasive aspergillosis, mucormycosis or
other species of lethal mold infection; if the infection was
expected to require therapy for >21 days (eg, bone and joint
infection, endocarditis); they had cystic fibrosis or moderate or
severe bronchiectasis; they had refractory septic shock not
responding to fluid resuscitation and/or vasopressors; severe
neutropenia (ie, <100 cells/μL blood); pregnancy; Acute
Physiology and Chronic Health Evaluation II (APACHE II)
score was >30; they had any condition that according to the
investigator would have compromised the safety of the patient
or the quality of the study data; they had previous exposure to
cefiderocol in this trial or previous exposure to another inves-
tigational study drug within 30 days prior to enrollment and
randomization; peritoneal dialysis; theymet diagnosis-specific
exclusion criteria. Each clinical diagnosis had specific exclu-
sion criteria, as shown in Table 1.
Randomization To Treatment And
Stratification
Patients were randomized 2:1 to receive IV therapy with
either cefiderocol 2 g, q8h, or BAT, and were stratified by
primary clinical diagnosis (HAP/VAP/HCAP, BSI/sepsis,
cUTI), APACHE II score (≤15 or ≥16–≤30), and region
(North America, South America region, Europe, Asia-
Pacific) (Figure 1). An interactive web or voice response
system was used to assign patients to identification num-
bers for which treatment had already been randomly
assigned. The population eligible for enrollment was
expected to result in approximately 50% of the patients
with HAP/VAP/HCAP, 30% with cUTI, and 20% with
BSI/sepsis.56 The APACHE II score was calculated based
on the measurements of individual components to estab-
lish the severity of the disease, and patients were stratified
as having APACHE II score ≤15 or ≥16. Patients were
enrolled in approximately 100 study sites in the USA,







1. Rapid diagnostics + informed consent
2. Treatment failure
3. Stenotrophomonas maltophilia
4. Local hospital antibiogram
5. Colonizer
Informed consent
Screening (Inclusion criteria/Exclusion criteria)
1. HAP/VAP/HCAP-specific I/E criteria
2. BSI/Sepsis-specific I/E criteria
3. cUTI-specific I/E criteria
Randomization & Stratification
1. Clinical diagnosis









End of  study
Figure 1 Patient flow in the CREDIBLE-CR study.
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Treatment Regimens
The study drug, cefiderocol 2 g, q8h, was infused over 3 hrs in
100mL solution. The dose was adjusted for patients with renal
impairment or augmented creatinine clearance (Table 2).
Patients with cUTI received cefiderocol as monotherapy,
whereas patients with HAP/VAP/HCAP or BSI/sepsis were
permitted to receive cefiderocol plus one additional antibiotic
(adjunctive therapy) belonging to one of the following classes:
aminoglycoside, macrolide, fluoroquinolone, penicillin
(including piperacillin-tazobactam, piperacillin, or ampicil-
lin-sulbactam), fosfomycin, tetracyclines (including tigecy-
cline). Polymyxin (colistin or polymyxin B), cephalosporins,
including new combinations with β-lactamase inhibitors or
carbapenems were not permitted as adjunctive therapy with
cefiderocol. The treatment duration was expected to be 7–14
days for HAP/VAP/HCAP or BSI/sepsis, and a minimum of 5
days for cUTI. The treatment duration could be extended up to
21 days if deemed necessary by the investigator.
BAT was the standard of care for CR infections at each
enrolling study site and could include up to three antibiotics
with Gram-negative coverage used in combination. BATwas
determined by the site investigator based on the assessment
of the patient’s clinical condition and had to be pre-specified
prior to randomization. BAT included locally approved anti-
biotics (maximum three antibiotics in combination) for the
treatment of the CR Gram-negative infection. The dosage of
BAT was adjusted according to the local country-specific
label. If the investigator used colistin or polymyxin B, the
dosing recommendations outlined by the EMA had to be
followed.64 De-escalation of BATwas allowed (eg, by redu-
cing the number of antibiotics given) based on the assess-
ment made at the early assessment (EA) time point.
Adjunctive aerosolized antibiotic treatment or step-down
to oral treatment was not allowed in the study. Concomitant
antibiotics were allowed if the patients had a confirmed/sus-
pected Gram-positive or anaerobic co-infection (eg, vancomy-
cin, daptomycin, linezolid, clindamycin, or metronidazole).
Clinical Assessments
Physical examination was performed, and vital signs,
Sequential Organ Failure Assessment (SOFA) score, oxygena-
tion status, and chest radiographs and Clinical Pulmonary
Infection Score (CPIS) in HAP/VAP/HCAP patients were
assessed at EA, end of therapy (EOT), test of cure (TOC),
and follow-up (FUP) time points. Creatinine clearance was
determined at screening and at the EA time point to confirm
whether dose adjustment for cefiderocol was required.
Microbiological Assessments
Appropriate clinical specimens were collected from
patients within 48 hrs prior to the start of infusion of the
first dose of study treatment. For patients who were
enrolled on the basis of treatment failure, clinical speci-
mens collected within 72 hrs prior to randomization could
be used as baseline screening culture. Clinical specimens
were sent to the local microbiology laboratory for culture
and susceptibility testing to document evidence of CR
pathogens. Once randomized, additional clinical speci-
mens were obtained at EA, EOT, TOC, and FUP time
points. Additionally, two blood samples were collected
from separate venipunctures regardless of the primary
Table 2 Dose Adjustment Of Cefiderocol In Patients With
Augmented Creatinine Clearance Or Renal Impairment.
Augmented renal function
(MDRD-eGFR ≥90 mL/min/1.73 m2 and CrCL
≥120 mL/min)a
2 g, q6h, 3-hr
infusion
Normal renal function
(MDRD-eGFR ≥90 mL/min/1.73 m2 and CrCL
<120 mL/min)a
2 g, q8h, 3-hr
infusion
Mild renal impairment
(MDRD-eGFR 60 to <90 mL/min/1.73 m2)
2 g, q8h, 3-hr
infusion
Moderate renal impairment
(MDRD-eGFR 30 to <60 mL/min/1.73 m2)
1.5 g, q8h, 3-hr
infusion
Severe renal impairment
(MDRD-eGFR 15 to <30 mL/min/1.73 m2)
1 g, q8h, 3-hr
infusion
ESRD (MDRD-eGFR <15 mL/min/1.73 m2) 0.75 g, q12h, 3-hr
infusion
Patient with intermittent hemodialysis 0.75 g, q12h, 3-hr
infusionb
CVVH 1 g, q12h, 3-hr
infusionc
CVVHD or CVVHDF 1.5 g, q12h, 3-hr
infusionc
Notes: aCrCL was calculated by Cockcroft–Gault equation at Screening. Urine mea-
sured CrCLwas calculated by using timed urine collections of 2–8 hrs at early assessment
(EA). bCefiderocol is hemodialysable, thus on dialysis days, a supplemental dose of 0.75 g
was administered as a 3-hr infusion after the completion of intermittent hemodialysis. If
the supplemental dose overlapped with the next regular dose, the investigator could
consider skipping either the next regular q12h dose or the supplemental dose to avoid an
excessive exposure and complexity of clinical operation. cThe dose was determined
based on MDRD-eGFR on non-dialysis days. Copyright © American Society for
Microbiology, [Antimicrobial Agents Chemotherapy, 61, 2017, e01381-16. doi: 10.1128/
AAC.01381-16.29
Abbreviations: MDRD-eGFR, modification of diet in renal disease-estimated glomer-
ular filtration rate calculated with the MDRD equation; CrCL, creatinine clearance;
ESRD, end-stage renal disease; CVVH, continuous venovenous hemofiltration;
CVVHD, continuous venovenous hemodialysis; CVVHDF, continuous venovenous
hemodiafiltration; q6h, every 6 hrs; q8h, every 8 hrs; q12h, every 12 hrs.
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site of infection within 48 hrs prior to the first dose of
study treatment. Subsequent blood cultures were required
if the baseline blood culture was positive.
● From HAP/VAP/HCAP patients, sputum, bronchoal-
veolar lavage, or protected brush specimen samples
were appropriate.
● For BSI patients, the blood sample collected at
screening had to be positive; for sepsis patients
(defined by the Systemic Inflammatory Response
Syndrome), the source of infection had to be an
anatomical location different from the source asso-
ciated with HAP/VAP/HCAP or cUTIs.
● For cUTI patients, the urine sample had to be posi-
tive for bacteria with clinical signs and symptoms of
infection present.
In order to expedite the enrollment of patients with CR
Gram-negative pathogens and initiate appropriate treat-
ment before culture and susceptibility results were avail-
able, rapid diagnostic methods or selective chromogenic
media could be used to identify patients with CR patho-
gens. Additionally, cultures of appropriate sites were per-
formed for species identification and antibiotic
susceptibility testing in the local microbiology laboratory.
All isolated pathogens were required to be frozen,
stored, and later sent to the central laboratory
(International Health Management Associates,
Schaumburg, Illinois) for confirmation of species identifi-
cation, antibiotic susceptibility, and molecular characteri-
zation of the mechanisms of carbapenem resistance.
Safety Assessments
Safety assessment in the safety population (defined below)
included physical examination, adverse event reporting,
laboratory investigations, vital signs assessment, and mor-
tality up to the end of study visit (ie, EOT + 28 days [± 3
days]). Mortality included those events that occurred due
to serious adverse events, which were ongoing at EOS
visit. Adverse events were recorded by System Organ
Class and Preferred Term according to MedDRA. The
severity of adverse events was graded as mild, moderate,
or severe, and its relationship to study treatment was
determined by the investigator. Clinical laboratory inves-
tigations included hematology, blood chemistry, and uri-
nalysis at subsequent time points during the study.
Additional laboratory testing was performed to assess
iron homeostasis parameters such as serum iron, hepcidin
level, transferrin iron saturation, and total iron-binding
capacity. Vital signs (daily) and 12-lead electrocardiogram
(at screening) were also recorded.
Outcome Definitions
Clinical outcomes assessed by the investigator were
defined for each diagnosis at EA (Day 3–4), EOT (last
day of treatment), TOC (EOT + 7 days [± 2 days]), and
FUP (EOT + 14 days [± 3 days]) time points. Clinical
outcomes were categorized as clinical cure, failure, or
indeterminate for each diagnosis at EA, EOT, and TOC
time points. At FUP, patients could have sustained clinical
cure, relapse, or indeterminate clinical outcome. The defi-
nitions of the clinical outcomes are included in Table 3.
An overall per-patient microbiological outcome was
determined based on individual microbiological outcomes
for each baseline pathogen. Microbiological outcomes
were categorized as eradication, persistence, or indetermi-
nate for each clinical diagnosis. At FUP, patients could
have sustained eradication, recurrence, or indeterminate
microbiological outcome. The definitions of the microbio-
logical outcomes are included in Table 4. Additionally, any
new pathogens isolated from appropriate biospecimens
were categorized as superinfection (ie, isolation of a new
pathogen from the primary infection site) or new infection
(ie, isolation of a new pathogen from a different infection
site).
Patient Populations
The intent-to-treat (ITT) population included all rando-
mized patients who received at least one dose of study
drug. The Microbiological ITT (Micro-ITT) population
included all ITT patients with a confirmed Gram-negative
pathogen at baseline from an appropriate clinical biospeci-
men. The CR-Micro-ITT (CR-MITT) included all Micro-
ITT patients who had a confirmed CR Gram-negative
pathogen at baseline. The CR-Microbiologically evaluable
(CR-ME) population included all CR-Micro-ITT patients
who had ≥5 days of IV treatment (unless the patient was
classified as treatment failure), completed the study, and
had valid assessment at TOC, and had no major protocol
violation. The safety population included all randomized
patients who received at least one dose of study drug, and
safety of the actual treatment received was assessed. The
PK population included all patients who received cefider-
ocol treatment and had a plasma sample collected for PK
evaluation of cefiderocol.
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Table 3 Definitions Of Clinical Outcome (response) Parameters
HAP/VAP/HCAP BSI/Sepsis cUTI
EA, EOT, TOC
Clinical cure Resolution or substantial improvement
of baseline signs and symptoms of
pneumonia including a reduction in
SOFA and CPIS scores, and
improvement or lack of progression of
chest radiographic abnormalities such
that no antibacterial therapy is required
for the treatment of the current
infection.
Resolution or substantial improvement
of baseline signs and symptoms
including a reduction in SOFA score,
such that no antibacterial therapy is
required for the treatment of BSI/
sepsis. Patients with bacteremia must
have eradication of bacteremia caused
by the Gram-negative pathogen.
Resolution or substantial improvement
of baseline signs and symptoms of cUTI,
or return to pre-infection baseline if
known, such that no antibacterial
therapy is required for the treatment of
the current infection.
Clinical failure No apparent response to therapy;
persistence or worsening of baseline
signs and/or symptoms of pneumonia;
reappearance of signs and/or symptoms
of pneumonia; development of new
signs and/or symptoms of pneumonia
requiring antibiotic therapy other than,
or in addition to, study treatment
therapy; progression of chest
radiographic abnormalities; or death
due to pneumonia.
No apparent response to therapy;
persistence or worsening of baseline
signs and/or symptoms, reappearance
of signs and/or symptoms; development
of new signs and/or symptoms
requiring antibiotic therapy other than,
or in addition to, study treatment
therapy; or death due to BSI/sepsis.
No apparent response to therapy;
persistence or worsening of baseline
signs and/or symptoms of cUTI; or
reappearance of signs and/or symptoms
of cUTI; development of new signs and/
or symptoms of cUTI requiring
antibiotic therapy other than, or in
addition to, study treatment therapy; or
death due to cUTI.
Indeterminate Lost to follow-up such that a
determination of clinical cure/failure
cannot be made.
Lost to follow-up such that a
determination of clinical cure/failure
cannot be made.
Lost to follow-up such that a





Continued resolution or substantial
improvement of baseline signs and
symptoms of pneumonia, such that no
antibacterial therapy is required for the
treatment of pneumonia in a patient
assessed as cured at TOC.
Continued resolution or substantial
improvement of baseline signs and
symptoms associated with reduction in
SOFA score, such that no antibacterial
therapy is required for the treatment of
the original BSI/sepsis in a patient
assessed as cured at TOC.
Continued resolution or improvement
of baseline signs and symptoms of cUTI,
or return to pre-infection baseline if
known, in a patient assessed as cured at
TOC.
Relapse Recurrence of signs and/or symptoms
of pneumonia, appearance of new signs
and/or symptoms of pneumonia, new
chest radiographic evidence of
pneumonia, or death due to pneumonia
in a patient assessed as cured at TOC.
Recurrence of signs and/or symptoms
of BSI/sepsis, appearance of new signs
and/or symptoms of the original BSI/
sepsis, or death due to BSI/sepsis in a
patient assessed as cured at TOC.
Recurrence of signs and/or symptoms
of cUTI, or appearance of new signs
and/or symptoms of cUTI in a patient
assessed as cured at TOC.
Indeterminate Lost to follow-up such that a
determination of clinical sustained cure/
relapse cannot be made, or patient
received additional antibacterial therapy
for the treatment of the current
infection.
Lost to follow-up such that a
determination of clinical sustained cure/
relapse cannot be made, or patient
received additional antibacterial therapy
for the treatment of the current
infection.
Lost to follow-up such that a
determination of clinical sustained cure/
relapse cannot be made, or patient
received additional antibacterial therapy
for the treatment of the current
infection.
Abbreviations: HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; HCAP, healthcare-associated pneumonia; BSI, bloodstream infection; cUTI,
complicated urinary tract infection; EA, early assessment; EOT, end of therapy; TOC, test of cure; SOFA, Sequential Organ Failure Assessment; CPIS, Clinical Pulmonary
Infection Score.
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Endpoints (Diagnosis Specific)
The primary endpoints of the study were: 1) clinical cure rates
at TOC in adult patients with HAP/VAP/HCAP or BSI/sepsis
caused by CRGram-negative pathogens in the CR-Micro-ITT
population; 2) microbiological outcomes at TOC in adult
patients with cUTI caused by CR Gram-negative pathogens
in the CR-Micro-ITT population. Secondary endpoints
included: clinical outcome (EOT, FUP), microbiological out-
come (EOT, TOC, FUP), and all-causemortality at Day 14 and
Day 28 for patients with HAP/VAP/HCAP or BSI/sepsis; and
microbiological outcome (EOT, FUP), clinical outcome (EOT,
TOC, FUP), and composite clinical and microbiological out-
come (EOT, TOC, FUP) for patients with cUTI. The safety of
cefiderocol or BAT was also investigated for all diagnoses.
Table 4 Definitions Of Microbiological Outcome (Response) Parameters
HAP/VAP/HCAP BSI/Sepsis cUTI
EA, EOT, TOC
Eradication Absence of the baseline Gram-negative
pathogen from an appropriate clinical
specimen. If it is not possible to obtain
an appropriate clinical culture and the
patient has a successful clinical
outcome, the response will be
presumed to be eradication.
Absence of the baseline Gram-negative
pathogen from a blood culture and/or
other primary source as applicable. In the
case of sepsis, if the patient has a successful
clinical outcome and it is not possible to
obtain an appropriate clinical culture, the
response will be presumed to be
eradication.
A urine culture shows the baseline
Gram-negative uropathogen found at
entry at ≥105 CFU/mL are reduced to
<103 CFU/mL.
Persistence Continued presence of the baseline
Gram-negative pathogen from an
appropriate clinical specimen.
Continued presence of the baseline
Gram-negative pathogen from a blood
culture or other primary source.
A urine culture shows that the baseline
Gram-negative uropathogen found at
entry at ≥105 CFU/mL grows ≥103 CFU/
mL.
Indeterminate No culture obtained from an
appropriate clinical specimen or
additional antibacterial therapy for the
treatment of the current infection
including missed sampling.
No culture obtained or additional
antibacterial therapy for the treatment
of the current infection including missed
sampling.
No urine culture obtained or additional
antibacterial therapy for the treatment





Absence of the baseline Gram-negative
pathogen from an appropriate clinical
specimen after TOC. If it is not possible
to obtain an appropriate clinical culture
and the patient has a successful clinical
response after TOC, the response will
be presumed to be eradication.
Absence of the baseline Gram-negative
pathogen from a blood culture or other
primary source after TOC as applicable.
In the case of sepsis, if the patient has a
successful clinical outcome after TOC
and it is not possible to obtain an
appropriate clinical culture, the
response will be presumed to be
sustained eradication.
A culture taken any time after
documented eradication at TOC, and a
urine culture obtained at FUP shows
that the baseline uropathogen found at
entry at ≥105 CFU/mL remains <103
CFU/mL.
Recurrence Recurrence of the baseline Gram-
negative pathogen from an appropriate
clinical specimen taken after TOC, and
the TOC culture is negative.
Recurrence of the baseline Gram-
negative pathogen from a blood culture
or other primary source after TOC, and
the TOC culture is negative.
A culture taken any time after
documented eradication at TOC, up to
and including FUP that grows the
baseline uropathogen ≥103 CFU/mL.
Indeterminate No culture obtained from an
appropriate clinical specimen or patient
received additional antibacterial therapy
for the treatment of the current
infection including missed sampling.
No culture or patient received
additional antibacterial therapy for the
treatment of the current infection
including missed sampling.
No urine culture or patient received
additional antibacterial therapy for the
treatment of the current infection
including missed sampling.
Abbreviations: HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; HCAP, healthcare-associated pneumonia; BSI, bloodstream infection; cUTI,
complicated urinary tract infection; EA, early assessment; EOT, end of therapy; TOC, test of cure; CFU, colony-forming unit.
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Other secondary endpoints included the composite endpoint of
survival without the need to change antibiotic treatment due to
lack of efficacy or presence of drug-related toxicity (TOC);
SOFA score (EOT, TOC, FUP); and CPIS (EOT, TOC, FUP)
in patients with HAP/VAP/HCAP.
Blood Sample Collection For PK Analysis
Of Cefiderocol
All patients who received cefiderocol treatment pro-
vided blood samples for sparse PK analysis of cefider-
ocol. The purpose was to determine any relationship
between actual drug exposure and clinical or micro-
biological outcomes (ie, PK/PD analyses). The blood
samples were taken on Day 3 during therapy just prior
to infusion, 1 hr after the start of infusion, at the end
of infusion, and 1 hr after the end of infusion. Patients
assessed with non-stable renal function at the EA time
point who required dose adjustment for cefiderocol
provided additional blood samples within 24–72 hrs
after dose adjustment, with four blood samples being
taken (ie, just prior to infusion, 1 hr after the start of
infusion, at the end of infusion, and 1 hr after the end
of infusion).
Statistical Analysis
As the CREDIBLE-CR study was not designed as a
non-inferiority or superiority study, no formal inferen-
tial analysis was planned. During discussions with reg-
ulatory agencies (ie, EMA), enrollment of
approximately 100 patients treated with cefiderocol
was recommended. Due to feasibility considerations
for total study enrollment, a 2:1 randomization ratio
was adopted to provide only 50 patients in the control
arm (BAT), providing a total sample size of approxi-
mately 150 enrolled patients.
The statistical analysis will be descriptive. The sum-
mary statistics for continuous variables will include the
number of subjects, arithmetic mean, standard deviation,
minimum, median, and maximum values. Categorical vari-
ables will be summarized by using frequency count and
the percentage of patients in each category. No hypotheses
have been pre-specified and no inferential testing has been
planned for primary or secondary outcomes. Missing data
for individual data points will remain as missing unless
otherwise stated in the Statistical Analysis Plan. SAS ver-
sion 9.2 or later will be used to analyze the data.
Discussion
Evolving Regulatory Environment
The global spread of carbapenem resistance in Gram-negative
bacteria has remained a great concern for the past 15–20
years.65–67 The Infectious Diseases Society of America has
published its “10 × ‘20” initiative for the urgent development
of 10 new antibiotic agents,68,69 but this initiative could not be
adopted specifically for CR infections under the regulatory
framework in either the USA (Food and Drug Administration
[FDA]) or Europe (EMA) at the time; thus, new guidance was
needed.70,71 Both the FDA and EMA introduced a new gui-
dance and/or changed their approach to enable pharmaceutical
companies to develop new antibiotics targeting resistant
pathogens, which are infrequently included in large, double-
blind, randomized, non-inferiority, active-controlled studies
designed for infection site-specific indications.56–58 Ongoing
discussions led to the alternative streamlined (or limited)
clinical development approach,56–59 which meant that the
efficacy and safety of a new candidate drug could be investi-
gated in different indications simultaneously, with appropriate
endpoints being defined for each individual indication.56–58
One important requirement of the US FDA is that the safety of
the drug must be supported by a “safety database” including
information of at least 300 patients.56 This has been achieved
in the randomized, double-blind, non-inferiority, Phase 2
APEKS-cUTI study.32 In the end, based on the discussions
with the EMA Scientific Advisory Committee (ie, Committee
for Medicinal Products for Human Use [CHMP]) in Europe,58
Shionogi gained acceptance of their strategy for the clinical
investigation of cefiderocol to specifically address CR infec-
tions, making the CREDIBLE-CR study pivotal for regulatory
approval in Europe.60
Rationale For Study Design And Patient
Population
The CREDIBLE-CR study is an open-label, randomized,
prospective, multinational, parallel-group, Phase 3 clinical
study to assess the safety and efficacy of cefiderocol for
the treatment of infections caused by CR bacteria where
the patient population is primarily defined by the presence
of these pathogens rather than the infection types, hence,
the term “pathogen-focused study.” Because of the enroll-
ment of a broad range of CR Gram-negative bacteria and
infection types, the control arm (BAT) was not fixed and
patients were allowed to receive up to three antibiotics to
be used in combination, making the study particularly
relevant to current real-world clinical practice.
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While the cUTI study (APEKS-cUTI32) and the
recently completed nosocomial pneumonia study
(APEKS-NP; NCT03032380) are both randomized, dou-
ble-blind, monotherapy clinical trials with inferential test-
ing of a hypothesis, they both exclude patients known to
have CR infections because the control drug is a carbape-
nem (imipenem-cilastatin or meropenem, respectively).
The CREDIBLE-CR study has made an effort to include
the CR infections that were excluded from the above-
mentioned studies and to provide at least descriptive evi-
dence of efficacy against the target pathogens.
The CREDIBLE-CR study accurately reflects the
patient population with high unmet medical need that is
most likely to benefit from treatment with cefiderocol. In
conventional Phase 3 clinical trials, many comorbidities,
immunosuppression, and short life expectancy are exclu-
sion criteria, which was not the case in the CREDIBLE-
CR study, and patients with such conditions could be
enrolled. Thus, the design of the study met the investiga-
tors’ expectations in terms of the target population.
The CREDIBLE-CR study has enrolled approximately
150 patients who were severely ill with HAP, VAP, HCAP,
BSI, sepsis, or cUTI, which were caused by CR pathogens.
The enrollment of patients with various diagnoses made it
possible to enrich the study population for a broad range of
CR pathogens. Patients were stratified by their baseline
diagnosis group (HAP/VAP/HCAP, BSI/sepsis, or cUTI),
region, and APACHE II score (Figure 1). These three main
stratification criteria will facilitate the comparison of out-
comes by treatment group in patients with less or more
severe conditions based on the APACHE II scores, and
across geographic regions with different rates of carbape-
nem resistance in all indications.
These diagnoses are reported with different underlying
all-cause mortality rates in real-world clinical practice (eg,
pneumonia with ~40%–60% rate and UTI with 5%–8.5%
rate),72–74 and all present a great challenge for physicians
because of the lack of uniformly effective and relatively
safe antibiotics for the treatment of CR pathogens. Due to
varying rates of expected all-cause mortality and/or attri-
butable mortality across the diagnoses, mortality was not
selected as the primary efficacy endpoint because a single
non-inferiority margin could not be selected for all sites of
infection. A superiority study design to investigate all-
cause mortality was an option to overcome the lack of a
single non-inferiority margin, but this was viewed as non-
realistic considering that these pathogens are rare and the
enrollment of a very large number of patients into the
study would have been necessary to demonstrate a treat-
ment benefit of cefiderocol over the comparator arm for
all-cause mortality. This feasibility issue was also
observed during the TANGO II and CARE pathogen-
focused Phase 3 clinical trials that addressed CRE infec-
tions. These studies enrolled a relatively low number of
patients who were infected by confirmed CRE (ie,
TANGO II: n=47; CARE: n=37) over a period of 2 to 3
years.75,76 Thus, setting a target of at least 150 patients
was a priority in the CREDIBLE-CR study in order to
ensure successful completion of enrollment and to collect
adequate data on efficacy and safety as well as thorough
PK data for patients treated with cefiderocol. Therefore,
based on the discussions with the EMA, clinical cure rate
was selected as the primary endpoint for patients with
pneumonia or BSI/sepsis, and microbiological eradication
rate was selected for patients with cUTI, with an overall
lower patient number at a 2:1 randomization ratio provid-
ing 100 patients who were treated with cefiderocol.
Due to the lack of a pre-specified hypothesis, the study
was not powered to detect statistically significant differ-
ences for the primary endpoints; the planned sample size
was aligned with the guidance from the EMA and only
descriptive statistics will be used. If such a pathogen-
focused study is conducted as a registration trial without
inferential statistical testing, the approved European label
of the agent will be restricted to the treatment of patients
infected by specific drug-resistant pathogens or pathogens
that have limited treatment options.58 Despite the fact that
the descriptive statistical analysis follows the guidance of
the EMA CHMP,58 we have found that this approach
within a study protocol and subsequent execution of a
clinical study needed additional strong scientific support
for ethics committee approval on a country-by-country
basis. Thus, designing future multi-national pathogen-
focused studies should be aligned with local institutional
board and ethics committee’s strategies.
Evidence Of Carbapenem Resistance
Evidence for carbapenem resistance was the key criterion for
enrollment into the CREDIBLE-CR study. Patients with only
suspected CR infections could not be enrolled. Efforts to
enrich patient populations in other pathogen-focused studies
without objective evidence of the target pathogens have pro-
ven problematic.75 In the CREDIBLE-CR study, the evidence
for carbapenem resistance could be provided by one of the five
different pathways. If a patient’s infection was a treatment
failure and the causative pathogen was confirmed as CR in
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routine culture and susceptibility testing, then the patient could
be enrolled. To broaden the origin of CR infections, alternative
pathways were also included: the use of rapid diagnostics that
allowed identification of carbapenemase genes directly from
patient biospecimens (eg, Gene Xpert CARBA-R), or selec-
tive media that identified carbapenem resistance, neither of
which has been proactively utilized in previous randomized
clinical trials. Rapid diagnostic methods can detect genes
encoding carbapenemases within 1 hr prior to obtaining results
from routine culture and susceptibility testing, with a positive
impact on therapeutic decision.47,49,50,52 However, significant
coordination between surgeons, infectious disease physicians,
pulmonologists, nurses or hospital staff was required prior to
requesting informed consent from patients or their family
members for the use of rapid diagnostics, particularly when
patients were very ill in the ICU. This could represent a
challenge to rapid enrollment into this type of study. The use
of selective chromogenic media for sputum and blood speci-
mens, or other specimen types, was slightly more problematic
because of the longer time required for confirmation (ie, over-
night incubation of the specimens).77 The use of thesemethods
expedited enrollment of patients within the allowed time win-
dow (ie, ≤24 hrs for cUTI patients and ≤36 hrs for other
diagnoses) specified in the study protocol. In contrast, some
previous studies allowed the enrollment of patients who could
have received potentially effective empiric antibiotic therapy
(ie, colistin-based regimens) for up to 96 hrs prior to
randomization.10,43,44 Initiating appropriate antibiotic therapy
early is crucial; thus, selecting the time window of prior
empiric antibiotic treatment when designing a randomized
clinical study to investigate the efficacy and safety of a poten-
tial new treatment option may have implications on outcomes.
The additional pathways included surveillance cultures identi-
fying carbapenem resistance from the same site of infection or
the identification of A. baumannii (or another multidrug-resis-
tant species) where the carbapenem resistance likelihood was
>90% based on the hospital’s antibiogram, or S. maltophilia,
which is intrinsically resistant to carbapenems.
Use Of Best Of Available Therapy
Unlike previous pathogen-focused studies (eg, RESTORE-
IMI,78 CARE76), which selected colistin-based comparator
regimens, the CREDIBLE-CR study used the “best available
therapy” in each enrolling country as a “control” group,
similarly to the TANGO II study.75 BAT was selected prior
to randomization by the investigator at each study site from
locally approved antibiotics and based on all available infor-
mation of the patient’s infection site and pathogen, including
susceptibility data. It was not feasible or appropriate to select
one specific comparator agent for the entire study because of
the multiple diagnoses and species involved, and up to three
agents were allowed in the BAT treatment group. Because
BAT could not be standardized across geographical regions
and could have been different even among hospitals in the
same country, blinding was not possible and the study was
designed as an open-label study. In addition, the availability
of new antibiotics (eg, the ceftazidime–avibactam combina-
tion approved by the US FDA, which has activity against
certain CREs) meant that BATcould have changed during the
study period in a participating hospital; thus, an open-label
design seemed more reasonable. The use of BAT as a “con-
trol” instead of a fixed comparator agent was well received
by the investigators and likely facilitated enrollment because
they have extensive experience with the currently available
agents for the treatment of such high-risk patients with CR
infections. The selection of BAT, which was supported by
scientific evidence, was also in accordance with the regula-
tory guidance by the EMA.58
Conclusion
This pioneering study will provide guidance for designing
future pathogen-focused studies. It is likely that clinicians
will come to expect similar pathogen-focused studies that
inform their clinical decision-making in other clinical devel-
opment programs for new antibiotics moving forward. Once a
satisfactory pathway from regulatory agencies has been estab-
lished and validated, patients and investigators may be more
likely to participate in pathogen-focused studies rather than
infection site-specific studies for the development of new
antibiotics for rare pathogens. It is our hope that the experience
gained through the CREDIBLE-CR study might serve as the
basis for additional studies, and potentially will help to design
future studies with the objectives of addressing more specific
clinical questions, for example, the role of combination ther-
apy, the use of empiric therapy, and for defining treatment and
management algorithms in addition to registration studies.
Data Sharing
Data sharing is not applicable to this manuscript because
no participants’ data are included.
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